RRML - Blastic plasmacytoid dendritic cell neoplasia – a rare type of acute leukemia
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English

Journal Metrics

Impact Factor 0.5
Five Year Impact Factor 0.5
JCI 0.12

Advanced search

Top 10 downloaded articles
- April 2024 -
 
A comprehensive review of Prof... 25
Recomandarea comună EFLM-COLA... 15
Anti-thyroid peroxidase (TPO) ... 11
Understanding the key differen... 10
Monocyte to high-density lipop... 10
Romanian Review of Laboratory ... 7
Understanding the pathogenesis... 7
Predictive value of expression... 7
Approaching Risk Management in... 6
Function of the S1P pathway in... 6

Log in

Concept, Design & Programming
Dr. Adrian Man
   
 
Nr. 22(1)/2014 DOI:10.2478/rrlm-2014-0010
XML
TXT

Blastic plasmacytoid dendritic cell neoplasia – a rare type of acute leukemia

Judit Beáta Köpeczi, Erzsébet Benedek, Enikő Kakucs, Aliz Tunyogi, Monica Istrati, Istvan Benedek


Abstract:

Blastic plasmacytoid dendritic cell neoplasm (BPDCN), recently classified among the acute myeloid leukemia and related precursor neoplasms, is a rare hematological malignancy with highly aggressive clinical course. We report a case of a 55 year-old female patient who presented spontaneous rupture of the spleen. The histopathological diagnosis without immunohistochemistry was splenic marginal zone non-Hodgkin lymphoma (NHL). The patient received 4 courses of polychemotherapy. Due to the unfavorable evolution the spleen was histopathologically reexamined and immunohistochemistry was performed in another laboratory. The diagnosis of NHL was excluded. Undifferentiated malignant cell proliferation, possible myeloid was suspected. Due to the discrepancy between diagnoses, a third immunohistological examination was performed in a third laboratory. NHL was excluded and myeloid, NK-cell or plasmacytoid dendritic cell leukemia was suspected. The patient was admitted to our clinic after 8 months from the initial diagnosis. Immunophenotyping by flowcytometry from the bone marrow showed 23% blasts positive for CD4, CD56, CD123, HLA-DR, CD38, CD11b, CD2, and negative for lineage specific markers of B-, T-lymphoid, NK- or myelomonocytic cells. The final diagnosis was BPDCN in leukemic phase. Due to the diversity of the clinical presentation, morphology and immunophenotype of BPDCN the diagnosis of this rare malignancy remains challenging. Immunophenotyping by flowcytometry is superior to immunohistochemistry because of the availability of a larger panel of antibodies and the possibility to identify the intensity of antigen expression. The atypical forms of BPDCN should be recognized early in order to manage properly the patients with this aggressive disease.

Keywords: blastic plasmacytoid dendritic cell neoplasm,CD4+/CD56+/lin- neoplasm,immunophenotyping,CD123

 
  PDF Download full text PDF
(874 KB)
     
 
How to cite
Köpeczi JB, Benedek E, Kakucs E, Tunyogi A, Istrati M, Benedek I. Blastic plasmacytoid dendritic cell neoplasia – a rare type of acute leukemia. Rev Romana Med Lab. 2014;22(1):69-77. DOI:10.2478/rrlm-2014-0010